What happened with the Noxopharm Limited (ASX:NOX) leadership team?

Noxopharm announced the resignation of its CEO and Managing Director, Dr Gisela Mautner, effective 14 April 2026. Dr Mautner has been with the biotech firm since 2019, originally serving as Chief Medical Officer before taking the top executive role in early 2022.

Why is Dr Gisela Mautner’s departure significant for Noxopharm (ASX:NOX)?

Dr Mautner oversaw a major shift in the company's strategic direction during her four-year tenure as a key executive. As the leader of a clinical-stage biotech, her departure creates a temporary leadership vacuum while the company works to advance its proprietary technology platforms.

Who is currently leading Noxopharm (ASX:NOX) following the CEO resignation?

The company has not yet named an interim or permanent replacement, though Chairman Fred Bart issued the official statement regarding the transition. Noxopharm management confirmed that the board expects to announce a successor in the "very near future."

What is the core business strategy of Noxopharm (ASX:NOX)?

Noxopharm is an Australian clinical-stage biotech company focused on developing novel treatments for cancer and inflammation. Its primary strategy revolves around two technology platforms: Sofra, which focuses on mRNA drug safety and inflammation, and Chroma, which targets oncology.

How did the market react to the Noxopharm (ASX:NOX) CEO resignation?

At the time of the announcement, Noxopharm’s share price was $0.058. In the short term, micro-cap biotech stocks often experience volatility following the loss of a key executive, as investors weigh the risks of leadership transition against the company's clinical pipeline progress.

What are the main risks for Noxopharm (ASX:NOX) investors right now?

The primary risks include "key person risk" and the uncertainty surrounding the new CEO's vision for the Sofra and Chroma platforms. Clinical-stage biotechs are highly speculative, and a change in leadership during critical trial phases can lead to shifts in timelines or capital allocation priorities.

Noxopharm CEO Dr Gisela Mautner announces resignation

Written by Brie CarterPublished Apr. 14 2026

Sydney-based clinical-stage biotech Noxopharm (ASX:NOX) has announced the resignation of its CEO and Managing Director, Dr Gisela Mautner, effective April 14.

Dr Mautner first joined the company in 2019 as chief medical officer before elevating to the top executive role in early 2022.

During her four-year tenure, she was credited by Chairman Fred Bart for overseeing a significant shift in the company’s strategic direction.

Noxopharm, which specialises in mRNA safety and treatments for cancer and inflammation through its Sofra and Chroma platforms, confirmed that a successor is expected to be named in the near future.

At the time of reporting, Noxopharm’s share price was $0.058.